Latest news with #ASGCTAnnualMeeting
Business Wire
13-05-2025
- Business
- Business Wire
Stylus Medicine Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stylus Medicine, Inc. ('Stylus'), a biotechnology company dedicated to developing transformative in vivo genetic medicines, today announced presentations showcasing its genome engineering approach and in vivo CAR-T platform at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting being held May 13-17, 2025 in New Orleans, Louisiana. 'On the heels of our company launch and Series A financing, the Stylus team is honored to present our work to the scientific community at this year's ASGCT Annual Meeting, highlighting our advances in recombinase engineering and demonstrating the therapeutic potential of our targeted LNP/recombinase-based in vivo CAR-Ts,' said Jason Fontenot, Ph.D., Chief Scientific Officer of Stylus Medicine. 'At Stylus, we are committed to realizing the revolutionary potential of genetic medicines. We are taking a focused 'medicines first' approach to build a potent, flexible, and scalable in vivo platform, with the goal of bringing the curative promise of CAR-T therapies to all patients in need.' ASGCT Annual Meeting Presentation Details: Oral Presentation: Title: Engineering High-Efficiency, High-Specificity Recombinases for Therapeutic In Vivo Genome Engineering Session: Novel Approaches to Gene Targeting and Gene Correction Presenter: Christopher J. Wilson, Ph.D., Senior Vice President, Genome Engineering Date, Time and Location: Abstract: 188 Summary: Stylus will present the development of therapeutic-grade recombinases for in vivo genetic medicines. The company reports engineering high-efficiency, high-specificity recombinases targeted to a novel safe harbor site in the human genome. The company's engineered recombinases act without the use of landing pads, protein fusions, or guide RNAs and possess a well-defined integration profile. These proprietary recombinases serve as the foundation of Stylus' powerful and elegant off-the-shelf, in vivo genetic medicines platform, which features single-step insertion of multi-kb therapeutic payloads. Poster Presentation: Title: Efficient and Effective In Vivo CAR-T Generation Using Recombinase-Based, Precise, High-Capacity, Off-the-Shelf, LNP-Based In Vivo Genomic Engineering Presenter: Celeste Richardson, Ph.D., Senior Vice President, Immunology Date and Time: Tuesday, May 13, 2025, 6:00 PM - 7:30 PM CT Abstract: 797 Summary: Stylus will present advances from its powerful and elegant in vivo CAR-T platform, which combines a proprietary recombinase that enables sequence-specific genome integration with cell-targeted lipid nanoparticle (LNP) delivery. Using a humanized NSG mouse tumor model, a single dose of the company's off-the-shelf in vivo CAR-T therapy demonstrated rapid and sustained tumor regression. By combining engineered recombinases with targeted LNP delivery, Stylus has created a platform to enable flexible and scalable in vivo CAR-T therapies, overcoming major limitations of ex vivo cell therapy. About Stylus Medicine Stylus Medicine is developing transformative in vivo genetic medicines to unlock cures. Stylus combines engineered recombinases with non-viral delivery to specifically encode therapeutics. The company's approach is versatile and modular, with potential therapeutic application across oncology, autoimmune, genetic diseases, and beyond. For more information about Stylus Medicine, please visit and follow us on LinkedIn.
Yahoo
13-05-2025
- Business
- Yahoo
Stylus Medicine Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting
CAMBRIDGE, Mass., May 13, 2025--(BUSINESS WIRE)--Stylus Medicine, Inc. ("Stylus"), a biotechnology company dedicated to developing transformative in vivo genetic medicines, today announced presentations showcasing its genome engineering approach and in vivo CAR-T platform at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting being held May 13-17, 2025 in New Orleans, Louisiana. "On the heels of our company launch and Series A financing, the Stylus team is honored to present our work to the scientific community at this year's ASGCT Annual Meeting, highlighting our advances in recombinase engineering and demonstrating the therapeutic potential of our targeted LNP/recombinase-based in vivo CAR-Ts," said Jason Fontenot, Ph.D., Chief Scientific Officer of Stylus Medicine. "At Stylus, we are committed to realizing the revolutionary potential of genetic medicines. We are taking a focused 'medicines first' approach to build a potent, flexible, and scalable in vivo platform, with the goal of bringing the curative promise of CAR-T therapies to all patients in need." ASGCT Annual Meeting Presentation Details: Oral Presentation: Title: Engineering High-Efficiency, High-Specificity Recombinases for Therapeutic In Vivo Genome Engineering Session: Novel Approaches to Gene Targeting and Gene Correction Presenter: Christopher J. Wilson, Ph.D., Senior Vice President, Genome Engineering Date, Time and Location: Thursday, May 15, 2025, 1:30 PM - 3:15 PM CT, New Orleans Theater B Abstract: 188 Summary: Stylus will present the development of therapeutic-grade recombinases for in vivo genetic medicines. The company reports engineering high-efficiency, high-specificity recombinases targeted to a novel safe harbor site in the human genome. The company's engineered recombinases act without the use of landing pads, protein fusions, or guide RNAs and possess a well-defined integration profile. These proprietary recombinases serve as the foundation of Stylus' powerful and elegant off-the-shelf, in vivo genetic medicines platform, which features single-step insertion of multi-kb therapeutic payloads. Poster Presentation: Title: Efficient and Effective In Vivo CAR-T Generation Using Recombinase-Based, Precise, High-Capacity, Off-the-Shelf, LNP-Based In Vivo Genomic Engineering Presenter: Celeste Richardson, Ph.D., Senior Vice President, Immunology Date and Time: Tuesday, May 13, 2025, 6:00 PM - 7:30 PM CT Abstract: 797 Summary: Stylus will present advances from its powerful and elegant in vivo CAR-T platform, which combines a proprietary recombinase that enables sequence-specific genome integration with cell-targeted lipid nanoparticle (LNP) delivery. Using a humanized NSG mouse tumor model, a single dose of the company's off-the-shelf in vivo CAR-T therapy demonstrated rapid and sustained tumor regression. By combining engineered recombinases with targeted LNP delivery, Stylus has created a platform to enable flexible and scalable in vivo CAR-T therapies, overcoming major limitations of ex vivo cell therapy. About Stylus Medicine Stylus Medicine is developing transformative in vivo genetic medicines to unlock cures. Stylus combines engineered recombinases with non-viral delivery to specifically encode therapeutics. The company's approach is versatile and modular, with potential therapeutic application across oncology, autoimmune, genetic diseases, and beyond. For more information about Stylus Medicine, please visit and follow us on LinkedIn. View source version on Contacts Company Contact Cecilia SunStylus Media Contact Amanda Lazaro1ABamanda@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
28-04-2025
- Business
- Business Wire
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine Sangamo abstracts for presentation at the 28 th ASGCT Annual Meeting being held May 13-17, 2025, in-person in New Orleans, LA and in a virtual format. Presentations will highlight the progression of Sangamo's neurology pipeline, including advances in zinc finger epigenetic regulation, the latest innovations in capsid delivery engineering, and developments in modular integrase technology. 'We are proud to be showcasing our latest pipeline advances at ASGCT, including three platform presentations, reflecting our mission to develop innovative neurology genomic medicines to treat debilitating neurological diseases,' said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. 'We are particularly excited to be presenting, in the prestigious Presidential Symposium, our potent combination of epigenetic regulation and capsid delivery capabilities as an anticipated one-time intravenous treatment for prion disease. It will be an honor to highlight the groundbreaking potential of our work and the dedication of our teams in advancing treatment options for neurology patients in need.' Data presentations at the ASGCT Annual Meeting include three oral presentations that detail Sangamo's advances in the application of zinc finger repressors (ZFRs) as a novel class of epigenetic regulation for neurological disease targets. Two presentations – including one taking place in the Presidential Symposium – showcase how Sangamo is combining its ZFR targeting the prion gene with STAC-BBB, its intravenously administered neurotropic capsid, for the treatment of prion disease, a fatal and incurable neurodegenerative disease. These presentations describe the profound survival benefits of the treatment in disease mouse models, and the sustained, brain-wide suppression of prion protein expression in both mouse and nonhuman primate models, supporting its potential as a one-time therapeutic approach for prion disease. The third presentation focuses on the advancement of ST-503, a ZFR targeting the gene encoding Nav1.7, for the treatment of intractable, chronic neuropathic pain following intrathecal delivery. Additional poster presentations at the ASGCT Annual Meeting will showcase advances in novel adeno-associated virus (AAV) capsid engineering and manufacturing for central nervous system (CNS) delivery. Topics range from second-generation STAC-BBB variants and receptor-targeted AAVs, to innovations in manufacturing and quality control, including strategies to enhance yield, purity, and stability, and improve analytical assessment of AAV products. Sangamo will also present updated data from its protein-guided MINT platform as an approach to enable engineering of large gene-sized pieces of DNA. Collectively, these abstracts highlight the versatility, durability, and translational potential of ZFR-based gene regulation across diverse neurological applications. ASGCT Annual Meeting Presentations and Invited Sessions Neurology Epigenetic Regulation Sustained Brain-wide Reduction of Prion via Zinc Finger Repressors in Mice and Nonhuman Primates as a Potential One-Time Treatment for Prion Disease Abstract No. 2 Oral Presentation – May 14; 11:30-11:45 am CT Session Title: Presidential Symposium Preclinical Development of an AAV-delivered Zinc Finger Transcriptional Repressor Targeting the Prion Gene as a Novel Epigenetic Gene Therapy for Prion Disease Abstract No. 389 Oral Presentation – May 17; 8:45-9:00 am CT Session Title: Pharmacology/Toxicology Studies and Analytics/Assay Development Session II AAV-Mediated Delivery of an Engineered Zinc Finger Lead to Selective and Potent Repression of Nav1.7 in Human Sensory Neurons and Nonhuman Primates DRG Nociceptors Following Intrathecal Injection Abstract No. 369 Oral Presentation – May 17; 8:45-9:00 am CT Session Title: Translational Approaches: Gene Therapy of Neurological Diseases in Large Animal Models AAV Engineering and Production for the Central Nervous System Fitness Maturation of STAC-BBB Yields Second-Generation Capsid Variants with Enhanced Delivery to the Central Nervous System Abstract No. 1909 Poster Presentation – May 15; 5:30-7:00 pm CT Characterization of Receptor-Targeted Blood-Brain Barrier Penetrant AAV Capsids Abstract No. 1896 Poster Presentation – May 15; 5:30-7:00 pm CT The Impact of Empty Capsids on AAV Manufacturing and Strategies for Enhancing Yield, Purity, and Stability in the Production of a Novel Blood-Brain Barrier Penetrant AAV Capsid Abstract No. 1464 Poster Presentation – May 14; 5:30-7:00 pm CT Recombinant Adeno-Associated Virus (rAAV) Production in Spodoptera Frugiperda (Sf9) Cells: Viral Cathepsin Mediated Capsid Cleavage and Mitigation Strategies Abstract No. 987 Poster Presentation – May 13; 6:00-7:30 pm CT Assessment of Adeno-Associated Virus (AAV) Purity by Capillary Electrophoresis-Based Western Abstract No. 1814 Poster Presentation – May 15; 5:30-7:00 pm CT Next-Generation Genome Engineering A Protein-Guided Modular Integrase (MINT) Platform Enables Compact Therapeutic Payloads and Efficient Targeted Integration in T Cells Abstract No. 648 Poster Presentation – May 13; 6:00-7:30 pm CT All abstracts for the ASGCT Annual Meeting are available on ASGCT's website. About Sangamo Therapeutics Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo's pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit and connect with us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, statements relating to Sangamo's technologies, the presentation of data from various therapeutic and research programs and the potential of these programs to demonstrate therapeutic benefit and transform the lives of patients. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the research and development process, including the results of clinical trials; the regulatory approval process for product candidates; and the potential for technological developments that obviate technologies used by Sangamo. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2024. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.
